Taiwan Liposome Company, Ltd. - ADRs (TLC): Price and Financial Metrics
TLC Price/Volume Stats
|Current price||$7.00||52-week high||$7.70|
|Prev. close||$7.00||52-week low||$4.07|
|Day high||$7.09||Avg. volume||133,095|
|50-day MA||$7.06||Dividend yield||N/A|
|200-day MA||$5.88||Market Cap||294.54M|
TLC Stock Price Chart Interactive Chart >
Taiwan Liposome Company, Ltd. - ADRs (TLC) Company Bio
Taiwan Liposome Company, Ltd. is a Taiwan-based company principally engaged in the research and development and commercialization of lipid drug delivery systems. The Company is engaged in the development of special generic drugs, new formulas and new drugs using patents. The Company's therapeutic areas include pain management, eye diseases and cancer. Its anticancer medicine product named Lipo-Dox has been distributed in domestic and Asian markets.
TLC Latest News Stream
|Loading, please wait...|
TLC Latest Social Stream
View Full TLC Social Stream
Latest TLC News From Around the Web
Below are the latest news stories about Taiwan Liposome Company Ltd that investors may wish to consider to help them evaluate TLC as an investment opportunity.
This communication does not constitute an offer of any securities for sale or subscription or a solicitation of an offer to purchase or subscribe to any securities in any jurisdiction. The securities to be issued pursuant to the stock swap transaction will not be registered under the U.S. Securities Act of 1933, as amended (the “Securities Act”), or under any relevant securities laws of any state or other jurisdiction of the United States. Such securities will be issued in reliance upon the exem
SOUTH SAN FRANCISCO, Calif. and TAIPEI, Taiwan, Aug. 12, 2021 (GLOBE NEWSWIRE) -- TLC, a clinical-stage specialty pharmaceutical company developing novel nanomedicines to target areas of unmet medical need, today announced financial results for the second quarter ended June 30, 2021 and provided a business update. “The second quarter of 2021 was marked mainly by the timely approval of our liposomal amphotericin B product in India and the immediate partnerships for their commercialization and sal
Ropivacaine Market 2021 SWOT Analysis, Competitive Landscape and Significant Growth | Top Brands:AstraZeneca, PainReform Ltd, Taiwan Liposome Company, Aspen Pharmacare, Encore Therapeutics, Celgene
This report studies the Ropivacaine Market with many aspects of the industry such as market size, market status, market trends and forecast. The report also provides brief information on competitors and opportunities for specific growth with the key market drivers. Find the comprehensive analysis of the Ropivacaine market segmented by company, region, type and applications 
Global Thymic Carcinoma Treatment Market 2021 Future Set to Massive Growth with High CAGR value | Market Players: Merck & Co., Inc., Sumitomo Dainippon Pharma Co., Ltd., Novartis AG, Onxeo SA, Tiziana Life Sciences Plc, Taiwan Liposome Company, Ltd.
The report on Global Thymic Carcinoma Treatment Market has been provided by researchers for a detailed understanding of market performance over an estimated period of time set from 2021 to 2026. However, this report has introduced a brief overview to provide the reader with better information on this report. This brief description contains a basic 
Looking for the next AMC, retail investors are on the hunt for the next squeeze.
TLC Price Returns
Continue Researching TLCWant to see what other sources are saying about Taiwan Liposome Company Ltd's financials and stock price? Try the links below:
Taiwan Liposome Company Ltd (TLC) Stock Price | Nasdaq
Taiwan Liposome Company Ltd (TLC) Stock Quote, History and News - Yahoo Finance
Taiwan Liposome Company Ltd (TLC) Stock Price and Basic Information | MarketWatch